Coya Therapeutics investor reports 5.3% ownership stake
Coya Therapeutics, Inc. received an updated ownership report on its common stock from investor Orin Hirschman and affiliated entities on a Schedule 13G/A (Amendment No. 3).
Rhea-AI Filing Summary
Coya Therapeutics, Inc. received an updated ownership report on its common stock from investor Orin Hirschman and affiliated entities on a Schedule 13G/A (Amendment No. 3).
Mr. Hirschman reports beneficial ownership of 1,108,171 shares, representing 5.3% of Coya’s common stock, with sole voting and dispositive power over these shares. AIGH Capital Management LLC reports beneficial ownership of 975,404 shares, representing 4.7% of the class, also with sole voting and dispositive power. The filing is made on a passive basis, stating the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Coya Therapeutics.
Positive
- None.
Negative
- None.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does this Schedule 13G/A filing reveal about COYA ownership?
Who is the reporting person in the COYA Schedule 13G/A?
What stake in COYA does AIGH Capital Management LLC report?
Is the COYA Schedule 13G/A filing made on a passive basis?
What type of securities are covered in this COYA Schedule 13G/A?
When did the ownership event for this COYA Schedule 13G/A occur?
AI-generated analysis. How Rhea-AI works. Not financial advice.